top of page

Ongoing Clinical Trials in

C3G Glomerulopathy

IPTACOPAN

Excessive local activation and dysregulation of the alternative complement pathway in the glomeruli can cause excessive deposition of multiple complement components in the glomerulus.

PEGCETACOPLAN

C3 is the point of convergence between all three complement pathways and the initiation of the terminal pathway. C3 inhibition is expected to block the entire complement system, including the classical pathway and C3b opsonization.

List of Updated Clinical Trials for
C3G Glomerulopathy

bottom of page